KLK3 and prostate carcinoma: Compared to other cancers, prostate cancer is characterized by three specific features: the progression rate is slow, the patient population is old with a median age at diagnosis of approximately 75 years and a specific tumor marker — the prostate specific antigen (PSA) is available to monitor progression even at an early stage [2–5].